Patheon to spend $45m on manufacturing plants ahead of Thermo takeover

By Gareth Macdonald

- Last updated on GMT


Related tags Thermo fisher scientific Thermo electron South carolina

Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.

The Netherlands-domiciled contractor announced the investment today, explaining it will add spray drying capacity at its plant in Florence, South Carolina, serialization tech at its Greenville, North Carolina site and expand its facility in Bend, Oregon.

Patheon also said it will build a new sterile product manufacturing facility in Monza, Italy and increase capacity at an existing plant at the site.

The new capabilities and plants – which are due to become operational in 2019 – are intended to cater for growing pharmaceutical industry demand for cost efficient and reliable supply chains according to Patheon president, Michel Lagarde.

With the increasing marketplace pressures, pharma companies are looking to build more reliable, flexible and cost-efficient supply chains​” he said.

News of the investment follows a month after Patheon announced it is due to me acquired by Thermo Fisher Scientific Inc. for $7.2bn​.

At the time Thermo Fisher cited the contractor’s small and large molecule contract manufacturing capacity, network of production plants and 9,000 staff as the driver for the deal.

Analysts including Evercore ISI’s Ross Muken highlighted the breadth of Patheon’s offering as a likely motivating factor for Thermo.

He said “Thermo brings unique relationships and market share at major BioPharma and Emerging Pharma which should synergize Patheon’s one stop shop approach​.” 

See how the deal will impact Thermo here​.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us


View more